Literature DB >> 4006484

Applicability of sample size calculations based on a comparison of proportions for use with the logrank test.

M H Gail.   

Abstract

The asymptotic relative efficiency of a test of proportions versus the logrank test is calculated for various clinical trial designs that are used to compare the survival of two treatment groups. The asymptotic relative efficiency is shown to be a reasonable guide to the relative sample sizes required for the logrank and proportions test. It is shown that the efficiency of the proportions test is near 1.0 for designs corresponding to typical studies of cardiovascular disease, for which the duration of the experiment is short compared to mean survival. This result is of practical importance, because sample size calculations based on the comparison of proportions are available to cover many contingencies, including a delay in the onset of full treatment effectiveness, whereas similar calculations have not been published for the logrank statistic. On the other hand, the efficiency of the proportions test can drop to 72% or less for trials in which the accrual period exceeds the mean survival, as is often the case in trials to treat cancer. In such cases, sample size calculations for the proportions test would be [(1/0.72) - 1] = 39% larger than required for the logrank test. Thus, power calculations specifically tailored to the logrank test should be used for studies with a duration comparable to mean survival, if one intends to employ the logrank statistic.

Entities:  

Mesh:

Year:  1985        PMID: 4006484     DOI: 10.1016/0197-2456(85)90116-3

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  4 in total

1.  Effect of pharmacist-led inhaler technique assessment service on readmissions in hospitalized COPD patients: a randomized, controlled pilot study.

Authors:  Adyam Tesfamariam Kebede; Elin Trapnes; Marianne Lea; Bjørg Abrahamsen; Liv Mathiesen
Journal:  BMC Pulm Med       Date:  2022-05-27       Impact factor: 3.320

2.  Statistical considerations for a trial of Ebola virus disease therapeutics.

Authors:  Michael A Proschan; Lori E Dodd; Dionne Price
Journal:  Clin Trials       Date:  2016-01-14       Impact factor: 2.486

3.  Effect of medicines management versus standard care on readmissions in multimorbid patients: a randomised controlled trial.

Authors:  Marianne Lea; Morten Mowé; Espen Molden; Kristin Kvernrød; Eva Skovlund; Liv Mathiesen
Journal:  BMJ Open       Date:  2020-12-29       Impact factor: 2.692

4.  Later is not necessarily better: limitations of survival analysis in studies of long-term drug treatment of psychiatric conditions.

Authors:  Joanna Moncrieff; Janus Christian Jakobsen; Max Bachmann
Journal:  BMJ Evid Based Med       Date:  2021-09-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.